DMC Group LLC Purchases 1,492 Shares of DexCom, Inc. (NASDAQ:DXCM)

DMC Group LLC boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 34.0% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 5,882 shares of the medical device company’s stock after purchasing an additional 1,492 shares during the period. DMC Group LLC’s holdings in DexCom were worth $394,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Crewe Advisors LLC purchased a new stake in DexCom in the 1st quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom in the second quarter worth about $25,000. Riverview Trust Co bought a new stake in shares of DexCom in the first quarter valued at approximately $32,000. Sachetta LLC raised its position in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares during the period. Finally, Sound Income Strategies LLC lifted its stake in shares of DexCom by 41.7% during the 1st quarter. Sound Income Strategies LLC now owns 340 shares of the medical device company’s stock valued at $47,000 after buying an additional 100 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. UBS Group reduced their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Robert W. Baird lifted their price target on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, August 5th. BTIG Research dropped their price objective on DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Baird R W lowered DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Finally, StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, October 12th. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average target price of $110.73.

DexCom Trading Up 4.1 %

Shares of DXCM opened at $72.38 on Friday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a market cap of $28.78 billion, a price-to-earnings ratio of 46.70, a PEG ratio of 2.16 and a beta of 1.18. The firm has a 50 day moving average price of $69.97 and a 200-day moving average price of $100.22. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the company earned $0.34 EPS. The firm’s revenue was up 15.3% compared to the same quarter last year. As a group, equities research analysts forecast that DexCom, Inc. will post 1.69 earnings per share for the current year.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the sale, the executive vice president now directly owns 66,249 shares in the company, valued at approximately $4,607,617.95. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,824 shares of company stock worth $126,390. Company insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.